Acurx Pharmaceuticals (FRA:3ZO0) Tariff Resilience Score: 8/10 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3ZO0 Acurx Pharmaceuticals Inc FRA:3ZO0
35 GF Score
Price €5.09
! 1 Warning Sign
View Full Analysis

What is Acurx Pharmaceuticals Tariff Resilience Score?

Acurx Pharmaceuticals FRA:3ZO0 35 Tariff Resilience Score is 8 as of Aug. 02, 2026. GuruFocus rates FRA:3ZO0 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,368 Biotechnology companies, Acurx Pharmaceuticals ranks better than 98.68% on this metric.

Acurx Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Acurx Pharmaceuticals has Acurx Pharmaceuticals has low tariff exposure, focusing on domestic R&D and benefiting from industry exemptions. The company has limited global supply chain dependencies and strong pricing power, making it resilient to tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Acurx Pharmaceuticals might have Highly Resilient.

Acurx Pharmaceuticals  (FRA:3ZO0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Acurx Pharmaceuticals Tariff Resilience Score Related Terms

FRA:3ZO0 vs KAPA, PULM, ADIL: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Acurx Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acurx Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Acurx Pharmaceuticals's Tariff Resilience Score falls into.


FRA:3ZO0
35GF Score
Acurx Pharmaceuticals Inc FRA:3ZO0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Acurx Pharmaceuticals (FRA:3ZO0) has a Tariff Resilience Score of 8 as of Aug. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Acurx Pharmaceuticals ranks #18 out of 1368 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Acurx Pharmaceuticals' Tariff Resilience Score too high?
Acurx Pharmaceuticals' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Acurx Pharmaceuticals' value of 8 is 100% above this industry median. Based on the distribution chart, Acurx Pharmaceuticals ranks #18 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acurx Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Tariff Resilience Score compare to KAPA and PULM?
According to the Biotechnology industry distribution chart, Acurx Pharmaceuticals ranks #18 out of 1368 companies for Tariff Resilience Score. This places Acurx Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Acurx Pharmaceuticals' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acurx Pharmaceuticals's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acurx Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (FRA:3ZO0) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Acurx Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Acurx Pharmaceuticals (FRA:3ZO0), the current Tariff Resilience Score is 8 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acurx Pharmaceuticals Business Description

Other Exchanges ACXP:USA
Address 259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
35GF Score

Get the complete analysis for FRA:3ZO0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09
Price